September 20, 2021
September 20, 2021 – TivdakTM (tisotumab vedotin-tftv) is now U.S. FDA approved to treat recurrent or metastatic cervical cancer in patients whose disease has progressed
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
International Health Insurance
September 20, 2021
December 20, 2021 – YusimryTM (adalimumab-aqvh), manufactured by Coherus BioSciences, has been
approved as a biosimilar for AbbVie's Humira® (adalimumab)
September 16, 2021
September 16, 2021 – Takeda's ExkivityTM (mobocertinib) has received U.S. FDA approval to treat adults
who have locally advanced or metastatic
September 16, 2021
September 16, 2021 – Pfizer is now recalling all lots of Chantix® (varenicline) 0.5mg and 1mg tablets in the United States due to excess levels of a nitrosamine called
September 16, 2021
September 16, 2021 – The U.S. FDA has approved two new indications for Brukinsa® (zanubrutinib), the first to treat adults who have Waldenström's macroglobulinemia
September 16, 2021
September 16, 2021 – The U.S. FDA has expanded the emergency use authorization (EUA) for Eli Lilly's investigation drugs bamlanivimab and etesevimab
September 13, 2021
September 13, 2021 – Jacobus Pharmaceutical Company recalled three lots of Ruzurgi® (amifampridine) 10mg tablets. Laboratory test found
September 12, 2021
September 17, 2022 – Cabometyx® (cabozantinib) is now U.S. FDA approved for to treat patients at least
12 years old who are radioactive iodine-refractory